CN110967482A - Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof - Google Patents
Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof Download PDFInfo
- Publication number
- CN110967482A CN110967482A CN201811165892.5A CN201811165892A CN110967482A CN 110967482 A CN110967482 A CN 110967482A CN 201811165892 A CN201811165892 A CN 201811165892A CN 110967482 A CN110967482 A CN 110967482A
- Authority
- CN
- China
- Prior art keywords
- rplo
- kit
- serum
- pyogenes
- goat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283707 Capra Species 0.000 title claims abstract description 50
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title description 11
- 238000002965 ELISA Methods 0.000 claims abstract description 42
- 108010006464 Hemolysin Proteins Proteins 0.000 claims abstract description 11
- 239000003228 hemolysin Substances 0.000 claims abstract description 11
- 238000008157 ELISA kit Methods 0.000 claims abstract description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- 210000002966 serum Anatomy 0.000 claims description 87
- 238000012360 testing method Methods 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 31
- 102000004190 Enzymes Human genes 0.000 claims description 31
- 230000000903 blocking effect Effects 0.000 claims description 29
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 26
- 238000005406 washing Methods 0.000 claims description 26
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 239000011248 coating agent Substances 0.000 claims description 21
- 238000000576 coating method Methods 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 239000013641 positive control Substances 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000013642 negative control Substances 0.000 claims description 13
- 239000002250 absorbent Substances 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 11
- 238000007865 diluting Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 239000012089 stop solution Substances 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 6
- 241001657377 Cryptobacterium Species 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 239000002274 desiccant Substances 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 238000001261 affinity purification Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 6
- 238000007605 air drying Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000424 optical density measurement Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 29
- 238000010790 dilution Methods 0.000 description 23
- 239000012895 dilution Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003000 inclusion body Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000565 sealant Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002981 blocking agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000037029 cross reaction Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000012474 protein marker Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- BOBBYBHJYYJHHQ-UHFFFAOYSA-N 7-tert-butyl-6-(4-chlorophenyl)-2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical group CC(C)(C)C1=NC=2NC(=S)NC(=O)C=2C=C1C1=CC=C(Cl)C=C1 BOBBYBHJYYJHHQ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 101150030193 Nanp gene Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- 108050008290 Serpin H1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 108091068033 cholesterol-dependent cytolysin family Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- -1 downstream of fstY Proteins 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 101150091858 ffh gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种检测山羊化脓隐秘杆菌间接ELISA试剂盒,其特征在于,所述试剂盒包含包被有山羊化脓隐秘杆菌重组溶血素rPLO的酶标板;所述rPLO的氨基酸序列如SEQ ID NO:1所示。本发明利用山羊化脓隐秘杆菌溶血素重组蛋白rPLO建立一种可准确检测山羊感染化脓隐秘杆菌的间接ELISA试剂盒。本试剂盒特异性强、灵敏度高、重复性好。
The present invention provides an indirect ELISA kit for detecting Cryptobacter pyogenes, which is characterized in that the kit comprises an ELISA plate coated with Cryptobacter pyogenes recombinant hemolysin rPLO; the amino acid sequence of the rPLO is as shown in SEQ ID NO:1 shown. In the invention, an indirect ELISA kit capable of accurately detecting the infection of the goat Cryptobacter pyogenes hemolysin recombinant protein rPLO is established. The kit has strong specificity, high sensitivity and good repeatability.
Description
Technical Field
The invention belongs to the field of biology, and particularly relates to a goat cryptococcus pyogenes infection detection kit, a preparation method and a use method thereof.
Technical Field
The purulent occult bacillus is a symbiotic bacterium of the mucous membranes of economical livestock such as cattle, sheep, pigs and the like, mainly parasitizes in the respiratory tract, the digestive tract and the genitourinary tract of animals, and is a component of normal flora. The purulent crypt bacillus is a conditioned pathogen, can invade through the skin and mucous membrane to cause adjacent tissue and organ infection, and can also be inhaled into the lung to cause lung and chest purulent pneumonia, purulent pleurisy and the like.
Cryptobacterium pyogenes is one of the main pathogens causing lymphadenitis on the body surface of goats and respiratory diseases of goats (Zhang Suhui et al, 2015). Clinically, sick sheep gradually get leaned and quickly breathe, and are accompanied by body surface lymphnoditis, abortion of pregnant ewes and the like. The dissection shows the lung with the suppurative focus of soybean size, lung with purulent lesion of chest wall, etc. The pathological section shows myocardial fibrosis, serous-cellulosic degeneration in the lung and renal tubule lumen, lymph node steatosis, inflammatory cell infiltration of liver, and serous-purulent inflammation of spleen. The treatment of pulmonary infection is difficult due to low plasma concentration in the lung. The disease is widely spread in southwest areas, and causes serious economic loss to goat breeding in the areas.
The identified virulence factors of cryptococcus pyogenes include hemolysin (PLO), collagen-binding protein (CbpA), neuraminidase (Nan) NanH and nanp.plo are the only exotoxins secreted by cryptococcus pyogenes, all isolates of cryptococcus pyogenes are capable of producing plo.billington, which is equal to the cryptococcus pyogenes PLO gene cloned in 1997, which has the full gene sequence of PLO open reading frame sharing 5bp, encoding 534 amino acids, with a molecular weight of 57.9 ku.plo gene located on 2.7kb gene island, upstream of orf121 open reading frame, downstream of fstY, ffh gene, PLO belonging to the cholesterol-dependent cytolysin Family (listeria pyogenes cytolysin, CDC), which is a member of the Family of cytolysins containing the pleurosporin, which is capable of inhibiting the development of the activity of the bacterial infection of human leukocytes by a number of human leukocyte antigen-induced apoptosis factor (plyos), which is capable of inhibiting the development of the growth of the bacterial infection of human leukocytes by a polymorphous cell-induced bacterial infection, which also includes the growth of human leukocyte antigen expressing pluronic leukocyte antigen (pleocidin), which is capable of inhibiting the development of the growth of human leukocyte-induced by human leukocyte.
Yan Ming Hui (2016), 2 monoclonal antibodies against PLO were prepared and confirmed that the critical regions of the antigen against which these 2 monoclonal antibodies were directed were amino acids 64 to 79 (i.e., VPVTKDQLKDG TYTVF) and 58 to 75 (i.e., GESIENVLKDGT) of PLO. This is also presented in patent application No. CN 201510616098.8. In CN201510616098.8, a recombinant plasmid pET-30a (+) -PLO containing a gene of Cryptococcus pyogenes PLO constructed by Muxiangli et al (2013, China veterinary Proc. 2013,35(06): 477) 480) is used at the same time to induce and express recombinant PLO without signal peptide, and the indirect ELISA method coated by the recombinant PLO is adopted to detect monoclonal antibody hybridoma culture cell supernatant or mouse ascites purified monoclonal antibody. The application of this "epitope polypeptide of crypthecium pyogenes PLO for preparing antibody reagents for detecting anti-crypthecium pyogenes PLO protein" is mentioned in the claim of CN201510616098.8, which does not refer to the contents of how to use recombinant PLO to establish a specific, sensitive, and highly reproducible indirect ELISA kit of crypthecium pyogenes.
The cryptobacter pyogenes is a new pathogen of goats, and the harm to goats is gradually known. Accurate and convenient diagnosis methods are needed to be used as technical supports for effective prevention and control, and the ELISA method is one of the optional methods for detecting and diagnosing the infection of the goat cryptobacter pyogenes. At present, a cryptobacter pyogenes ELISA diagnostic kit suitable for the basement layer is lacked.
Disclosure of Invention
Therefore, the indirect ELISA kit capable of accurately detecting the goat infected cryptococcus pyogenes is established by utilizing the goat cryptococcus pyogenes hemolysin recombinant protein rPLO. The kit has strong specificity, high sensitivity and good repeatability.
The purpose of the invention is realized by the following measures:
an indirect ELISA kit for detecting goat occult pyogenes, which is characterized by comprising an ELISA plate coated with goat occult pyogenes recombinant hemolysin rPLO; the amino acid sequence of the rPLO is shown as SEQ ID NO. 1.
The coating amount of the rPLO on a 96-well enzyme label plate is 0.2-1 mug/well, and the coating condition is 37 ℃ for 2-4 h.
The preparation method of the recombinant hemolysin rPLO comprises the following steps: the goat cryptococcus pyogenes PLO gene fragment is amplified through PCR, the rPLO gene fragment is cloned to pET28a, and the recombinant protein is expressed through a prokaryotic system.
Further, the rPLO gene fragment is cloned into a recombinant vector of pET28a and transformed into escherichia coli BL21(DE3), and IPTG is added for induction expression; and (3) carrying out affinity purification on the expression product rPLO by using a 6 XHis tag and a nickel column to obtain a purified recombinant rPLO antigen.
The goat crypthecium pyogenes PLO gene fragment is cloned into pET28a, IPTG induction expression is used in escherichia coli BL21(DE3), immunoblot analysis proves that goat serum immunized by crypthecium pyogenes, goat serum naturally infected by crypthecium pyogenes and mouse serum artificially infected by crypthecium pyogenes can identify the expression product, and the amino acid sequence of the recombinant hemolysin rPLO which can be identified by the crypthecium pyogenes specific serum is shown in SEQ ID NO: 1.
The rPLO obtained by the invention is efficiently expressed in the form of inclusion body, and can be expressed and purified in large quantity, so that the rPLO can meet the requirement of industrial production.
Furthermore, the preparation method of the ELISA plate coated with the Cryptococcus pyogenes rPLO comprises the following steps:
1) diluting rPLO with 0.05mol/L sodium carbonate buffer solution with pH9.6, adding into an enzyme label plate, and coating amount is 0.2-1 μ g/hole;
2) covering an enzyme label plate with a sealing plate film, and incubating for 2h at 37 ℃;
3) discarding the liquid in the wells of the ELISA plate, adding a washing solution into the wells, standing for 1min, and repeating for 3-5 times. After discarding the liquid in the hole each time, patting the residual liquid on absorbent paper to be dry;
4) blocking the ELISA plate by 0.01mol/L pH7.2 phosphate buffer solution containing 5% skimmed milk powder or 1-5% gelatin;
5) placing the enzyme label plate at 37 ℃ for 2h, incubating, removing liquid in the hole, and patting dry on absorbent paper;
6) adding phosphate buffer solution containing 5-20% of sucrose and having pH of 0.01mol/L into the wells of the ELISA plate, incubating at room temperature for 3-5h, removing the liquid in the wells, naturally drying, and vacuum-pumping and sealing with a packaging bag containing a desiccant.
Further, the kit comprises an enzyme-labeled antibody, wherein the enzyme-labeled antibody is rabbit anti-goat IgG labeled by horseradish peroxidase. And the enzyme-labeled antibody is subpackaged into 25 mL/bottle.
Further, the kit further comprises: sample diluent, washing solution, negative control serum, positive control serum, substrate developing solution A, B and stop solution.
Furthermore, the positive control serum is collected from goat serum containing PLO antibody after immunization of goat with Cryptobacterium pyogenes or rPLO.
Further, the sample diluent and the washing solution contain ProClin 300.
The negative control serum is healthy goat serum which is not infected with cryptococcus pyogenes.
Specifically, the formulations of the sample diluent, the washing solution, the substrate developing solution A, B and the stop solution are as follows:
sample diluent: PBS: 8g/L NaCl, 0.2g/L KCl, 3.58g/L Na2HPO4·12H2O,0.272g/LKH2PO41.0g/L BSA, 1.0mL/L ProClin300, dissolved in deionized water. Subpackaging into 40 mL/bottle.
10 times of concentrated washing solution: 80g/L NaCl, 2g/L KCl, 35.8g/L Na2HPO4·12H2O,2.72g/LKH2PO410mL/L ProClin300, dissolved in deionized water. Subpackaging into 40 mL/bottle.
Substrate color development liquid A: 6.8g/L of sodium acetate, 0.8g/L of citric acid and 0.15ml/L of 30% hydrogen peroxide are dissolved in distilled water. Subpackaging in brown bottle, 15 mL/bottle.
Substrate color developing solution B: disodium EDTA 0.1g/L, citric acid 0.475g/L, glycerin 25mL/L, 3,3',5,5' -Tetramethylbenzidine (TMB) powder 0.075g/L (0.15g of TMB powder first dissolved in 3mL of DMSO), dissolved in distilled water. Subpackaging in brown bottle, 15 mL/bottle.
Stopping liquid: 108.7mL of concentrated sulfuric acid (98%) is added dropwise into 891.3mL of distilled water to obtain a 2mol/L sulfuric acid solution, and the solution is mixed uniformly. Subpackaging into 15 mL/bottle.
The invention also provides application of the kit in detecting the infection of the goat cryptobacter pyogenes.
An application method of an indirect ELISA kit for detecting goat cryptobacter pyogenes comprises the following steps:
1) and (3) taking the enzyme label plate (coated with rPLO) out of the kit, and diluting the serum sample to be detected by 50 times by using a sample diluent. Sucking 100 mu L of diluted serum into an enzyme label plate, and simultaneously setting two holes of positive control serum and negative control serum, wherein each hole is 100 mu L/hole;
2) incubating at 37 deg.C for 30 min;
3) discarding liquid in the hole, adding 300 mu L/hole washing solution into the hole, standing for 1min, repeatedly washing for 3 times, and patting dry residual liquid in the hole on absorbent paper;
4) adding 100 mu L of enzyme-labeled antibody into each hole;
5) incubating at 37 ℃ for 30 min;
6) discarding liquid in the hole, adding 300 mu L/hole washing solution into the hole, standing for 1min, repeatedly washing for 3 times, and patting dry residual liquid in the hole on absorbent paper;
7) adding 50 mu L of substrate color developing solution A and substrate color developing solution B into each hole, slightly shaking and uniformly mixing to avoid overflowing of liquid in the holes;
8) incubating at 37 ℃ for 15 min;
9) adding 50 mu L of stop solution into the hole;
10) measuring and recording the OD of the test sample and the control450The value is obtained.
The kit of the invention has the following judgment standards: average OD of negative control450Less than 0.4, the mean value of the positive control is largeThe test is effective at 1.0.
S is sample OD450Value, P is OD of positive control450Average value. If the S/P value is more than 0.5, the sample is judged to be positive to the infection of the cryptobacter pyogenes. If the S/P value is less than or equal to 0.5 but greater than 0.4, the sample should be retested. If the test result is not changed, the sampling detection is carried out again after a certain time interval. And if the S/P value is less than 0.5 in the retest result, the sample is judged to be negative to the infection of the cryptobacter pyogenes. And (5) redoing if the experiment has no effect.
Advantageous effects
1. The invention provides a recombinant hemolysin rPLO which can be identified by goat specific serum immunized by goat cryptococcus pyogenes. The protein realizes high-efficiency expression in the form of inclusion body, can obtain at least 40mg of purified rPLO per 100mL of culture, has high yield, and can meet the requirement of industrialized production.
2. The indirect ELISA kit for detecting the infection of the goat cryptococcus pyogenes is established by using the cryptococcus pyogenes recombinant hemolysin rPLO and the use method thereof, and has the following effective effects: (1) the specificity is strong, and the infection of the cryptococcus pyogenes can be distinguished from the common goat pyogenic bacterial infection; (2) the sensitivity is high; (3) the method is simple to operate, is suitable for rapid diagnosis of the basic layer, and does not need to separate, culture and identify pathogenic bacteria according to the traditional method; (4) the detection time is short, and the detection is finished within 2 hours; (5) the preservation period of the product can reach 1 year at the temperature of 2-8 ℃.
Drawings
FIG. 1 shows the results of double digestion of recombinant plasmid pET28a-plo
M: marker; 1: recombinant plasmid pET28a-plo
FIG. 2 is an analysis of PLO gene induced expression
M: a protein Marker; 1: rPLO; 2: no induction was performed.
FIG. 3 is the result of the recognition of rPLO by goat serum immunized with Cryptococcus pyogenes culture (immunoblot) M: a protein Marker; 1: rPLO.
FIG. 4 soluble expression analysis of rPLO
M: a protein Marker; 1: precipitating; 2: supernatant fluid; 3: no induction was performed.
FIG. 5 shows the results of rPLO purification
M: a protein Marker; 1: purified rPLO; 2: dissolving the inclusion body; 3: inclusion body washing.
FIG. 6 shows the results of blocking experiments.
Detailed Description
Hereinafter, preferred embodiments of the present invention will be described in detail. The experimental methods of the preferred embodiments, which do not indicate specific conditions, are generally performed according to conventional conditions, and the examples are given for better illustration of the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art should make insubstantial modifications and adaptations to the embodiments of the present invention in light of the above teachings and remain within the scope of the invention.
EXAMPLE 1 preparation of rPLO
1. Construction of expression vector and recombinant Strain
A goat cryptococcus pyogenes PLO gene fragment is amplified through PCR, a target gene is cloned into pET28a, and a BL21(DE3) recombinant strain is constructed. The amino acid sequence of the cloned and expressed PLO is shown as SEQ ID NO. 1, and the theoretical molecular weight of the recombinant hemolysin rPLO is 33.5 kD.
2. Inducible expression
Inoculating the single colony of the recombinant engineering bacteria into 2mL liquid LB culture medium (containing 50mg/L kanamycin), shaking and culturing at 37 ℃ overnight, transferring fresh liquid LB culture medium (containing 50mg/L kanamycin) in a ratio of 1%, and shaking and culturing at 37 ℃ until the bacterial concentration reaches OD600When the concentration is 0.6, IPTG is added at a concentration of 0.1mmol/L, and the mixture is cultured at 37 ℃ with shaking at 180r/m for 3 hours. SDS-PAGE was used to analyze the expression induced by the recombinant protein.
As can be seen from FIG. 2, rPLO is clearly expressed.
3. Antiserum preparation
TSB culture medium is prepared, and the mixture is sterilized by autoclaving at 121 ℃ for 15 min. And (3) selecting a single colony of the goat cryptococcus pyogenes, inoculating the single colony to a TSB culture medium, and shaking at 37 ℃ for 72h for culture. To the culture was added 0.1% formaldehyde solution and inactivated at 37 ℃ with shaking every 5h for 24 h. Adding Freund's adjuvant for emulsification, and first-time immunizing emulsifier prepared with Freund's complete adjuvant and second-time immunizing emulsifier prepared with Freund's incomplete adjuvant. The goat is immunized by injecting emulsifier into 5mL per muscle, 2 weeks are separated between each immunization, blood is collected before immunization and serum is separated, and the blood is collected 2 weeks after the last immunization and the serum is separated.
4. Antibody recognition
Centrifuging 1mL of the above induction culture at 12000g/min for 1min, adding 100 μ L of 2 × sample buffer into the precipitate, suspending the thallus, subjecting to boiling water bath for 10min, performing SDS-PAGE, and performing immunoblotting. The antiserum is diluted by 1:1000, and the secondary antibody is donkey anti-sheep IgG antibody marked by alkaline phosphatase and diluted by 1: 2000. The color developing agent is BCTP/NBT.
As can be seen in FIG. 3, rPLO was recognized by goat antiserum immunized against Cryptobacterium pyogenes of goats, producing a specific band consistent with the expected size.
5. Soluble expression analysis
Performing induced expression rPLO according to the method, centrifuging to collect thalli, adding 20mL PBS per 100mL culture to suspend thalli precipitation, and ultrasonically cracking bacterial suspension in ice-water bath (the ultrasonic power is 300W, the working time is 4s, the interval is 5s, and the ultrasonic cracking time is 15 min). 100 μ L of lysate was centrifuged at 12000g/min for 1min, and the pellet and supernatant were subjected to SDS-PAGE, respectively, to analyze the soluble expression of rPLO.
As can be seen in FIG. 4, rPLO was abundant in the induced culture pellet and no apparent rPLO was present in the supernatant, indicating that rPLO was expressed as inclusion bodies.
6. Recombinant protein purification
Dissolving the inclusion body by 8mol/L urea, eluting by a sample, washing the hybrid protein and imidazole solution, and purifying the recombinant protein by Ni-NTA affinity chromatography. The effect of recombinant protein purification was analyzed by SDS-PAGE, the purity was analyzed by gray-scanning the band of interest with Image Lab3.0, and the concentration of purified protein was determined using BCA kit.
As can be seen in FIG. 5, rPLO was purified from inclusion body lysates by Ni-NTA affinity purification to 40mg rPLO per 100mL of culture as determined by BCA kit assay and Image Lab3.0 analysis.
The inventors also performed the above-described experiments using the fragments shown in SEQ ID NO. 2 to SEQ ID NO. 6, which were not recognized by goat antiserum immunized with Cryptobacterium pyogenes, could not form inclusion bodies, and could not appear in the induced culture pellet.
Example 2 optimization of Indirect ELISA conditions
1. Determination of optimal coating concentration and optimal serum dilution
The extracted rPLO was diluted 1:100 (8.55. mu.g/mL), 1:200 (4.28. mu.g/mL), 1:400 (2.14. mu.g/mL) and 1:800 (1.07. mu.g/mL) with pH9.6 carbonate buffer and added to wells of an enzyme-labeled plate, 100. mu.L per well, overnight at 4 ℃. The next day, wash the plate 3 times with PBST, 200. mu.L/well, 5min each time. 200 u L/hole 2% BSA, 37 degrees 2h all blocked. After blocking, the plates were washed 3 times for 5min with PBST. The positive and negative sera were diluted at 1:50, 1:100, 1:200, 1:400, 1:800 and 1:1600 to form a square matrix, which was repeated twice. Diluting enzyme-labeled antibody labeled by Horse Radish Peroxidase (HRP) at a ratio of 1:10000, adding into an enzyme-labeled plate at a concentration of 100 μ L/well, and keeping the temperature at 37 ℃ for 1 h. Washing for 4 times. The remaining steps were performed according to a conventional indirect ELISA procedure. In the specific embodiment, the ELISA plate used in each example is a 96-well ELISA plate.
And (4) judging a result: and (4) taking the antigen-antibody working concentration with the maximum P/N value as the optimal dilution in the titration result of the matrix method.
2. Coating temperature and time optimization
The ELISA plate was coated with the determined rPLO concentration, the coating conditions were set to 4 ℃ for 12h and 24h, respectively, and at 37 ℃ for 1h, 2h, 3h and 4h, for 6 groups, with two replicates per group. Serum was diluted at the determined optimal dilution, HRP-labeled enzyme-labeled antibody was diluted 1:10000, and the rest were tested according to the conventional indirect ELISA procedure. The group with the largest P/N value is taken as the optimal antigen coating condition.
3. Selection of type of blocking agent and blocking time
3.1 selection of blocking Agents
The ELISA plate was coated under the optimal conditions, 7 test groups were set with the non-blocking group as the control group, and blocking was performed with 10% fetal bovine serum, 5% skim milk powder, 1% gelatin, 5% gelatin, 0.1% BSA, 0.5% BSA, and 3% BSA as blocking agents, respectively. The blocking conditions were 37 ℃ for 1.5 h. HRP enzyme-labeled antibody was diluted 1: 10000. The remainder were tested according to the conventional indirect ELISA procedure. And selecting the group with the OD value of the closed group lower than that of the non-closed group and the maximum P/N value as the optimal sealant.
3.2 selection of the blocking time
The ELISA plates were coated and blocked under optimal conditions for l h, 1.5h and 2h at 37 ℃. Serum is diluted by the determined optimal dilution factor, HRP enzyme-labeled antibody is diluted by 1:10000, and other conventional indirect ELISA programs are used for testing, and the group with the maximum P/N value is used as the optimal blocking time.
4. Determination of optimal reaction time between serum and antigen
Coating and sealing the ELISA plate under the optimal condition, adding the serum diluted by the optimal dilution factor, and respectively acting for 0.5h, 1h, 1.5h and 2h at 37 ℃. HRP enzyme-labeled antibody was diluted 1:10000, and the remainder was tested according to a conventional indirect ELISA procedure. The group with the largest P/N value was used as the optimal action time of the serum.
Determination of optimal working concentration and optimal action time of HRP-labeled antibody
5.1 optimal working concentration of HRP-labeled antibody
According to the determined optimal condition test, the dilutions of HRP-labeled rabbit anti-goat IgG were set as: 1:8000, 1:16000, 1:32000, 1:64000, 1:128000, 1:256000, 1:51200, the rest were operated according to a conventional indirect ELISA procedure, and the group with the largest P/N value was used as the optimal working concentration of the HRP-labeled antibody.
5.2 optimal working time for HRP-labeled antibody
According to the determined optimal working concentration of the HRP-labeled antibody, the test is divided into 4 groups of 0.5h, 1h, 1.5h and 2h at 37 ℃ according to the action time. The rest of the procedures were performed according to the conventional indirect ELISA procedure, and the group with the largest P/N value was used as the optimal action time of the HRP-labeled antibody.
Selection of the color development time of the TMB
Performing test according to the determined optimal conditions, setting the color development time to be 5min, 10min, 15min and 20min at 37 ℃, and performing other operations according to a conventional indirect ELISA program, wherein the group with the maximum P/N value is used as the optimal color development time of the substrate.
The experimental results are as follows:
(1) determination of optimal coating concentration of antigen and optimal dilution of serum
The optimal antigen coating concentration and the optimal serum dilution were screened, and it was found that the OD values all decreased with increasing positive serum dilution when the antigen sample was diluted 80, 160, 320 and 640 times, respectively. Positive serum OD when rPLO was diluted 320-fold (2.14. mu.g/mL) and serum was diluted 50-fold450The value is more than 1.00, the P/N ratio is maximum, so the optimal coating concentration of the antigen is 2.14 mu g/mL, and the coating amount of the antigen can be determined to be 0.2 mu g-1 mu g/hole; the optimal dilution of serum was 1:50 and the results are shown in Table 1.
TABLE 1 determination of optimal dilution of antigen and serum
(2) Optimization of coating conditions
The OD value of the positive serum increases along with the prolonging of the coating time at 37 ℃, the coating time is 2-4h at 37 ℃, and the P/N value is in a peak interval. Therefore, the antigen coating conditions can be set to 37 ℃ for 2-4 h. The results are shown in Table 2.
TABLE 2 coating Condition optimization test results
(3) Selection of type of blocking agent and blocking time
The P/N value of the sealant is obviously higher than that of other sealants by using 5% of skimmed milk powder or 1-5% of gelatin as the sealant. The results are shown in Table 3. 5% skimmed milk powder or gelatin is used as a sealant, and when the sealant is sealed for 2h, the P/N value is the maximum and is 6.690. Thus, the optimal blocking time for antigen coated plates was 2 h. The results are shown in Table 4.
TABLE 3 selection of classes of blocking agents
TABLE 4 selection of blocking time
(4) Selection of serum duration of action
As can be seen from Table 5, the OD value of the positive serum increased and the P/N value increased with the increase of the serum action time within 0.5-1.5h, but the difference was not obvious.
TABLE 5 selection of serum action time
(5) Selection of dilution times and incubation times of HRP-labeled antibodies
As can be seen from table 6, the OD values of the positive and negative sera tended to decrease with increasing dilution of HRP-labeled antibody. When the HRP-labeled antibody was diluted 64000-fold, the P value was 1.581, the N value was 0.295, and the P/N maximum was 5.359. Thus, the optimal dilution factor for HRP-labeled antibody was 64000 fold.
TABLE 6 selection of dilution factor for HRP-labeled antibodies
The HRP-labeled antibody was diluted 64000 times with the HRP-labeled antibody for the optimal reaction time test, and the results are shown in Table 7. When the reaction time of the HRP-labeled antibody is within 0.5-2h, the P/N value is in a descending trend along with the time. The results show that the optimal working time of the HRP-labeled antibody is 0.5h at 37 ℃.
TABLE 7 selection of reaction time for HRP-labeled secondary antibodies
(6) Selection of TMB development time
As can be seen from Table 8, when the color was developed for 15min, the P value was 1.517, the N value was 0.318, and the P/N ratio was the largest and was 4.770. The optimal color development time of TMB was 15 min.
TABLE 8 selection of TMB development time
Example 3 Indirect ELISA method Main technical index test
1. Specificity test
1.1 Cross-over test
Preparing oil emulsion antigens from culture bacteria of Escherichia coli, Staphylococcus aureus, Streptococcus and Corynebacterium pseudotuberculosis, and immunizing goat. Separating serum, detecting by established indirect ELISA method, and establishing positive serum control and negative serum control of goat cryptococcus pyogenes. And judging whether the serum of the bacteria is positive to the goat cryptobacter pyogenes antibody or not according to the S/P value.
Detection effectiveness and cross reaction judgment standard: average OD of negative control450Less than 0.4, positive controls with an average value greater than 1.0 are considered effective. S is sample OD450Value, P is OD of positive control450Average value. If the S/P value is greater than 0.5, the sample should be judged as positive for cross-reaction. If the S/P value is less than or equal to 0.5 but greater than 0.4, the sample should be retested. If the S/P value is less than 0.4, the cross reaction is negative.
1.2 blocking assay
Taking the positive serum of the goat cryptococcus pyogenes as a multiple dilution, dividing the positive serum of each dilution into two parts from 1:50 to 1:1600, and adding the rPLO protein with the optimal dilution ratio in the same volume into one part, wherein the part is a blocking group; the other portion was added with an equal volume of coating buffer, which is a blocking control group. The treated serum was incubated at 37 ℃ for 1.5h and centrifuged at 10000rpm for 20 min. Negative sera were also diluted 2-fold from 1:50 to 1:1600 for 6 dilutions. Experiments were performed under the determined optimal reaction conditions and the blocking rate was calculated. The blocking rate was calculated as follows:
the blocking rate is (OD value of blocking control-OD value after blocking) ÷ OD value of blocking control × 100%.
The detection results of the cross test are shown in Table 9, the S/P values of the antiserum of escherichia coli, staphylococcus aureus, streptococcus and corynebacterium pseudotuberculosis are all less than 0.4, namely the rPLO has no cross reaction with the serum. The indirect ELISA method established by the test has better specificity.
TABLE 9 Cross test
Remarking: "-" indicates negative, and "+" indicates positive.
The blocking test results are shown in table 10 and fig. 6. When the serum dilution times are fixed, the OD value of the blocking group is obviously lower than that of the blocking control group, and the blocking rate is more than 60 percent, which indicates that the rPLO can block the reaction of positive serum and the positive serum. The result shows that the indirect ELISA method established by the test has good specificity.
TABLE 10 blocking test
2. Repeatability test
2.1 in-Board repeat test
Taking 3 parts of serum, carrying out tests on the same ELISA plate according to determined conditions, and carrying out detection on each part of serum by 3 times in a repeated way for 6 times. The in-plate coefficient of variation was calculated for each serum.
2.2 repeat test between plates
3 portions of serum are taken and respectively tested on 4 enzyme label plates according to the determined conditions, and each portion of serum is repeated for 4 times. The interplate coefficient of variation was calculated for each serum.
The in-plate reproducibility test results are shown in Table 11. The in-plate variation coefficients of the three serum samples are respectively 8.11%, 8.07% and 4.91%, and are all less than 10%, and the indirect ELISA method established by the test has good in-plate repeatability.
TABLE 11 in-Board repeatability test results
Remarking: the coefficient of variation is standard deviation/average × 100%.
The results of the plate-to-plate reproducibility tests are shown in Table 12. The coefficients of variation between plates for the three serum samples were 8.18%, 3.14% and 5.16%, respectively, all less than 10%. The indirect ELISA method established by the test has good repeatability between plates.
TABLE 12 results of the plate-to-plate repeatability tests
Remarking: the coefficient of variation is standard deviation/average × 100%.
3. Sensitivity test
Diluting the occult purulenta positive serum by 2 times, diluting 7 times from 1:200 to 1:6400, detecting by using an established indirect ELISA method without diluting the occult purulenta negative serum, and determining the highest serum dilution with positive detection result. S/N>2 is judged to be positive, S is the OD of the sample450Value, N is OD of negative control450Average value.
As can be seen from table 13, the OD value of the goat cryptobacter pyogenes-positive serum decreased with the increase in dilution factor, and when the serum was diluted 8000 times, the OD value was 0.401, and 2.554 > 2, which was found to be positive. When the serum was diluted 16000 times, the OD was 0.262, and 0.262/0.157 was 1.669 <2, which was judged negative. The highest serum dilution of which the detection result shows that the antibody of the goat cryptococcus pyogenes is positive is 1:8000, and the indirect ELISA method established by the test has higher sensitivity.
TABLE 13 sensitivity test results
4. Shelf life
Adding 0.01mol/LpH7.4 phosphate buffer solution containing 5% sucrose into the wells of the ELISA plate, incubating at room temperature for 3h, discarding the liquid in the wells, naturally drying, placing the ELISA plate into a packaging bag containing a drying agent, vacuumizing, sealing, and storing at 2-8 deg.C. And taking out the kit at regular intervals, detecting standard positive serum, standard negative serum and quality control serum, and evaluating main technical indexes of the kit such as specificity, sensitivity and the like.
The test shows that the kit can be placed for 15 months at the temperature of 2-8 ℃ and the effective period is as long as 1 year.
EXAMPLE 4 preparation and Assembly of the kits
1. The preparation method of the ELISA plate coated with the cryptococcus pyogenes rPLO comprises the following steps:
1) diluting rPLO prepared in example 1 with 0.05mol/L sodium carbonate buffer solution with pH9.6, adding into 96-well enzyme label plate, and coating amount is 0.2-1 μ g/well;
2) covering an enzyme label plate with a sealing plate film, and incubating at 37 ℃ for 2-4 h;
3) discarding liquid in the holes of the enzyme label plate, adding a washing solution into the holes, standing for 3min, repeating for 3-5 times, and after discarding the liquid in the holes each time, patting the residual liquid on absorbent paper to be dry;
4) blocking the ELISA plate by 0.01mol/L pH7.2 phosphate buffer solution containing 5% skimmed milk powder or 1-5% gelatin;
5) placing the enzyme label plate at 37 ℃ for 2h, incubating, removing liquid in the hole, and patting on absorbent paper to dry;
6) adding phosphate buffer solution containing 5-20% of sucrose and having pH of 0.01mol/L into the wells of the ELISA plate, incubating at room temperature for 3-5h, removing the liquid in the wells, naturally drying, and vacuum-pumping and sealing with a packaging bag containing a desiccant.
2. The enzyme-labeled antibody is rabbit anti-goat IgG labeled by horseradish peroxidase. The enzyme-labeled antibody is subpackaged into 25 mL/bottle.
3. The positive control serum is collected from goat serum containing PLO antibody after immunizing goat with Cryptococcus pyogenes or rPLO. The positive control serum was diluted with the sample diluent and split into 1 mL/tube.
4. The negative control serum is healthy goat serum without infecting cryptococcus pyogenes. The negative control serum was diluted with the sample diluent and dispensed into 1 mL/tube.
5. Preparation of a sample diluent: PBS: 8g/L NaCl, 0.2g/L KCl, 3.58g/L Na2HPO4·12H2O,0.272g/L KH2PO41.0g/L BSA, 1.0mL/L ProClin300, dissolved in deionized water. Subpackaging into 40 mL/bottle.
Preparation of 6.10-fold concentrated washing solution: 80g/L NaCl, 2g/L KCl, 35.8g/L Na2HPO4·12H2O,2.72g/L KH2PO410mL/L ProClin300, dissolved in deionized water. Subpackaging into 40 mL/bottle.
7. Preparation of a substrate color developing solution A: 6.8g/L of sodium acetate, 0.8g/L of citric acid and 0.15ml/L of 30% hydrogen peroxide are dissolved in distilled water. Subpackaging in brown bottle, 15 mL/bottle.
8. Preparation of a substrate color developing solution B: disodium EDTA 0.1g/L, citric acid 0.475g/L, glycerin 25mL/L, 3,3',5,5' -Tetramethylbenzidine (TMB) powder 0.075g/L (0.15g of TMB powder first dissolved in 3mL of DMSO), dissolved in distilled water. Subpackaging in brown bottle, 15 mL/bottle.
9. Preparation of a stop solution: 108.7mL of concentrated sulfuric acid (98%) is added dropwise into 891.3mL of distilled water to obtain a 2mol/L sulfuric acid solution, and the solution is mixed uniformly. Subpackaging into 15 mL/bottle.
10. Kit assembly
According to each component prepared by the preparation method, 2 enzyme label plates coated and sealed are configured according to each kit, and 1 bottle of each sample diluent, 10-time concentrated cleaning solution, negative control serum, positive control serum, substrate developing solution A, substrate developing solution B, enzyme labeled antibody and stop solution and 1 part of operation instruction are assembled.
EXAMPLE 5 method of Using the kit
The use method of the kit comprises the following steps:
1) and (3) taking the ELISA plate coated with rPLO out of the kit, diluting the serum sample to be detected by 50 times with a sample diluent, and sucking 100 mu L of mixed solution into the ELISA plate. Setting two holes of positive control serum and negative control serum, 100 mu L/hole, and diluting the negative serum and positive serum by 50 times according to the sample diluent for the serum to be seen;
2) incubating at 37 ℃ for 30 min;
3) discarding liquid in the hole, adding 300 mu L/hole washing solution into the hole, standing for 3min, repeatedly washing for 3 times, and patting dry residual liquid in the hole on absorbent paper;
4) adding 100 mu L of enzyme-labeled antibody into each hole;
5) incubating at 37 ℃ for 30 min;
6) discarding liquid in the hole, adding 300 mu L/hole washing solution into the hole, standing for 3min, repeatedly washing for 3 times, and patting dry residual liquid in the hole on absorbent paper;
7) adding 50 mu L of substrate color developing solution A and substrate color developing solution B into each hole, slightly shaking and uniformly mixing to avoid overflowing of liquid in the holes;
8) incubating at 37 ℃ for 15 min;
9) adding 50 mu L of stop solution into the hole;
10) measuring and recording the OD of the test sample and the control450The value is obtained.
The kit of the invention has the following judgment standards: average OD of negative control450Less than 0.4, positive controls with an average greater than 1.0 are effective in the test orientation.
S is sample OD450Value, P is OD of positive control450Average value. If the S/P value is more than 0.5, the sample is judged to be positive to the infection of the cryptobacter pyogenes. If the S/P value is less than or equal to 0.5 but greater than 0.4, the sample should be retested. If the test result is not changed, a timing should be separatedAnd (4) sampling again after a while, and detecting that the S/P value is less than 0.5, so that the sample is judged to be negative to the infection of the cryptobacter pyogenes. If the experiment is invalid, the experiment should be redone.
SEQUENCE LISTING
<110> institute of zootechnics in Chongqing City
<120> indirect ELISA method for detecting goat cryptobacter pyogenes infection
<160>
<210>1
<211>245
<212>protein
<213> Artificial (Artificial sequence)
<400>1
TDGLSAPRAS ISPMDKVDLK SAQETNETSV DKYIRGLKYD PSGVLAVKGE SIENVPVTKD 60
QLKDGTYTVF KHERKSFNNL RSDISAFDAN NAHVYPGALV LANKDLAKGS PTSIGIARAP 120
QTVSVDLPGL VDGKNKVVIN NPTKSSVTQG MNGLLDGWIQ RNSKYPDHAA KISYDETMVT 180
SKRQLEAKLG LGFEKVSAKL NVDFDAIHKR ERQVAIASFK QIYYTASVDT PTSPHSVFGP 240
NVTAQ 245
<210>2
<211>253
<212>protein
<213> Artificial (Artificial sequence)
<400>2
DLKDRGVNNK NPLGYISSVS YGRQIFVKLE TTSTSNDVQA AFSGLFKAKF GNLSTEFKTK 60
YADILNKTRA TVYVVGGSAR GGVEVATGNI DALKKIIKEE STFSTKVPAV PVSYAVNFLK 120
DNQLAAVRSS GDYIETTATT YKSGEITFRH GGGYVAKFRL KWDEISYDPQ GKEIRTPKTW 180
SGNWVGRTAG FRETIQLPAN ARNIHVEAGE ATGLAWDPWW TVINKKNLPL VPHREIVLKG 240
TTLNPWVEEN VKP 253
<210>3
<211>125
<212>protein
<213> Artificial (Artificial sequence)
<400>3
TDGLSAPRAS ISPMDKVDLK SAQETNETSV DKYIRGLKYD PSGVLAVKGE SIENVPVTKD 60
QLKDGTYTVF KHERKSFNNL RSDISAFDAN NAHVYPGALV LANKDLAKGS PTSIGIARAP 120
QTVSV 125
<210>4
<211>120
<212>protein
<213> Artificial (Artificial sequence)
<400>4
DLPGLVDGKN KVVINNPTKS SVTQGMNGLL DGWIQRNSKY PDHAAKISYD ETMVTSKRQL 60
EAKLGLGFEK VSAKLNVDFD AIHKRERQVA IASFKQIYYT ASVDTPTSPH SVFGPNVTAQ 120
<210>5
<211>120
<212>protein
<213> Artificial (Artificial sequence)
<400>5
DLKDRGVNNK NPLGYISSVS YGRQIFVKLE TTSTSNDVQA AFSGLFKAKF GNLSTEFKTK 60
YADILNKTRA TVYVVGGSAR GGVEVATGNI DALKKIIKEE STFSTKVPAV PVSYAVNFLK 120
DNQL 124
<210>6
<211>120
<212>protein
<213> Artificial (Artificial sequence)
<400>6
AAVRSSGDYI ETTATTYKSG EITFRHGGGY VAKFRLKWDE ISYDPQGKEI RTPKTWSGNW 60
VGRTAGFRET IQLPANARNI HVEAGEATGL AWDPWWTVIN KKNLPLVPHR EIVLKGTTLN 120
PWVEENVKP 129
Claims (10)
1. An indirect ELISA kit for detecting goat occult pyogenes infection, which is characterized by comprising an ELISA plate coated with goat occult pyogenes recombinant hemolysin rPLO; the amino acid sequence of the rPLO is shown as SEQ ID NO. 1.
2. The kit of claim 1, wherein the amount of rPLO coating on the microplate is 0.2-1 μ g/well.
3. The kit of claim 1 or 2, wherein the rPLO is prepared by a method comprising the steps of: the goat cryptococcus pyogenes PLO gene fragment is amplified through PCR, the rPLO gene fragment is cloned to pET28a, and the recombinant protein is expressed through a prokaryotic system.
4. The kit of claim 3, wherein the recombinant vector is transformed into E.coli BL21(DE3), and IPTG is added for inducible expression; and (3) carrying out affinity purification on the expression product rPLO by using a 6 XHis tag and a nickel column to obtain a purified recombinant rPLO antigen.
5. The kit of any one of claims 1-4, wherein the rPLO-coated microplate is prepared by a method comprising the steps of:
(1) diluting the purified rPLO with 0.05mol/L sodium carbonate buffer solution with pH9.6, adding into the well of an enzyme-labeled plate, and coating the rPLO with the amount of 0.2-1 mu g/well;
(2) attaching a sealing plate membrane to the ELISA plate, and incubating at 37 ℃ for 2-4 h;
(3) discarding liquid in the pores of the enzyme label plate, adding a washing solution into the pores, standing for 1min, repeating for 3 times, discarding the liquid in the plate after each washing, and patting the residual liquid in the pores on absorbent paper after the washing solution is discarded after the last washing;
(4) blocking the enzyme label plate by 0.01mol/L phosphate buffer solution with pH7.2 containing 5% skimmed milk powder or 1-5% gelatin, incubating at 37 deg.C for 2h, removing blocking solution, washing for 3 times, patting on absorbent paper, and air drying;
(5) vacuum-pumping and sealing with packaging bag containing desiccant, and storing at 2-8 deg.C.
6. The kit of claims 1-5, wherein the kit comprises an enzyme-labeled antibody that is horseradish peroxidase-labeled rabbit anti-goat IgG.
7. The kit according to any one of claims 1 to 6, wherein the kit comprises a substrate color developing solution A, B, and the color developing substrates A, B mainly comprise hydrogen peroxide and 3,3',5,5' -tetramethylbenzidine, respectively.
8. The kit of any one of claims 1 to 7, wherein the kit comprises a positive control serum obtained from a goat after immunization of the goat with inactivated Cryptobacterium pyogenes or rPLO with goat serum containing PLO antibodies.
9. The kit according to any one of claims 1 to 8, wherein the kit comprises a sample diluent, a washing solution, a negative control serum, a positive control serum, a substrate developing solution A, B, and a stop solution; the sample diluent contains ProClin 300.
10. The method of using the kit of any one of claims 1 to 9, comprising the steps of:
(1) diluting a serum sample to be detected by 50 times by using a sample diluent, taking 100 mu L of diluted serum to a hole of an enzyme label plate, and simultaneously setting two holes of positive control serum and negative control serum, wherein each hole is 100 mu L;
(2) incubating at 37 ℃ for 30 min;
(3) discarding liquid in the pores of the enzyme label plate, adding 300 mu L of washing liquid into each pore, standing for 1min, repeating for 3 times, discarding the liquid in the plate after washing each time, and patting the residual liquid in the pores on absorbent paper;
(4) adding 100 mu L of enzyme-labeled antibody into each hole;
(5) incubating at 37 ℃ for 30 min;
(6) repeating the step (3);
(7) adding 50 mu L of substrate color developing solution A and substrate color developing solution B into each hole, and slightly shaking and uniformly mixing;
(8) incubating at 37 ℃ for 15 min;
(9) adding 50 mu L of stop solution into each hole;
(10) OD measurement Using microplate reader450Reading the value;
(11) and judging whether the test is established or not, and calculating the S/P ratio to judge whether the sample to be detected is positive or negative.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811165892.5A CN110967482B (en) | 2018-09-30 | 2018-09-30 | Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811165892.5A CN110967482B (en) | 2018-09-30 | 2018-09-30 | Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110967482A true CN110967482A (en) | 2020-04-07 |
CN110967482B CN110967482B (en) | 2023-04-07 |
Family
ID=70029552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811165892.5A Active CN110967482B (en) | 2018-09-30 | 2018-09-30 | Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110967482B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112611864A (en) * | 2020-12-03 | 2021-04-06 | 重庆市畜牧科学院 | System and method for screening germ models |
CN113985026A (en) * | 2021-09-29 | 2022-01-28 | 重庆市畜牧科学院 | ELISA kit for detecting mycobacterium paratuberculosis in sheep and application thereof |
CN115927420A (en) * | 2022-05-27 | 2023-04-07 | 贵州省畜牧兽医研究所 | Hemolysin recombinant expression and indirect ELISA detection method and application |
CN115925829A (en) * | 2022-07-22 | 2023-04-07 | 东北农业大学 | Application of rHtaA-c protein in preparation of vaccine for preventing Cryptobacterium pyogenes |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101949928A (en) * | 2010-08-26 | 2011-01-19 | 江苏出入境检验检疫局动植物与食品检测中心 | Kit for detecting alpaca mycobacterium paratuberculosis antibody and detection method thereof |
CN102079781A (en) * | 2010-04-22 | 2011-06-01 | 中国疾病预防控制中心寄生虫病预防控制所 | Immunogenic protein in schistosoma japonicum soluble egg antigen as well as screening method and application thereof |
CN103543261A (en) * | 2013-09-13 | 2014-01-29 | 中国农业科学院特产研究所 | Cattle and sheep brucellosis indirect enzyme-linked immunosorbent assay antibody detection kit and preparation method thereof |
WO2014058876A1 (en) * | 2012-10-08 | 2014-04-17 | Cornell University | Compositions and methods for diagnosis and prophylaxis of mastitis in ruminants |
US20150140034A1 (en) * | 2013-09-19 | 2015-05-21 | Zoetis Llc | Oil-based adjuvants |
CN106996928A (en) * | 2016-01-22 | 2017-08-01 | 上海复星长征医学科学有限公司 | A kind of magnetic bead chemical luminescence reagent kit for detecting tuberculosis infection and its application |
CN107106635A (en) * | 2014-11-21 | 2017-08-29 | 俄克拉何马大学董事会 | Pneumolysin mutant and its application method |
CN108048588A (en) * | 2018-01-17 | 2018-05-18 | 重庆市畜牧科学院 | The detection primer and detection kit of a kind of Arcanobacterium pyogenes |
-
2018
- 2018-09-30 CN CN201811165892.5A patent/CN110967482B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102079781A (en) * | 2010-04-22 | 2011-06-01 | 中国疾病预防控制中心寄生虫病预防控制所 | Immunogenic protein in schistosoma japonicum soluble egg antigen as well as screening method and application thereof |
CN101949928A (en) * | 2010-08-26 | 2011-01-19 | 江苏出入境检验检疫局动植物与食品检测中心 | Kit for detecting alpaca mycobacterium paratuberculosis antibody and detection method thereof |
WO2014058876A1 (en) * | 2012-10-08 | 2014-04-17 | Cornell University | Compositions and methods for diagnosis and prophylaxis of mastitis in ruminants |
CN103543261A (en) * | 2013-09-13 | 2014-01-29 | 中国农业科学院特产研究所 | Cattle and sheep brucellosis indirect enzyme-linked immunosorbent assay antibody detection kit and preparation method thereof |
US20150140034A1 (en) * | 2013-09-19 | 2015-05-21 | Zoetis Llc | Oil-based adjuvants |
CN105764525A (en) * | 2013-09-19 | 2016-07-13 | 硕腾服务有限责任公司 | Oil-based adjuvants |
CN107106635A (en) * | 2014-11-21 | 2017-08-29 | 俄克拉何马大学董事会 | Pneumolysin mutant and its application method |
CN106996928A (en) * | 2016-01-22 | 2017-08-01 | 上海复星长征医学科学有限公司 | A kind of magnetic bead chemical luminescence reagent kit for detecting tuberculosis infection and its application |
CN108048588A (en) * | 2018-01-17 | 2018-05-18 | 重庆市畜牧科学院 | The detection primer and detection kit of a kind of Arcanobacterium pyogenes |
Non-Patent Citations (4)
Title |
---|
KEISUKE IMAIZUMI 等: "Analysis of the functional domains of Arcanobacterium pyogenes pyolysin using monoclonal antibodies" * |
孟祥莉;母晓宇;刘晓丹;徐凝;王璞;高明春;张文龙;王君伟;: "化脓隐秘杆菌溶血素蛋白的原核表达及其溶血活性鉴定" * |
田凯;王秋霞;郭文洁;朱竟赫;刘耀川;刘明春;: "化脓隐秘杆菌溶血素的研究进展" * |
许国洋 等: "山羊淋巴结炎病原菌的分离鉴定及多重PCR检测方法的建立" * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112611864A (en) * | 2020-12-03 | 2021-04-06 | 重庆市畜牧科学院 | System and method for screening germ models |
CN112611864B (en) * | 2020-12-03 | 2024-03-12 | 重庆市畜牧科学院 | System and method for screening germ model |
CN113985026A (en) * | 2021-09-29 | 2022-01-28 | 重庆市畜牧科学院 | ELISA kit for detecting mycobacterium paratuberculosis in sheep and application thereof |
CN113985026B (en) * | 2021-09-29 | 2023-12-26 | 重庆市畜牧科学院 | ELISA kit for detecting sheep mycobacterium paratuberculosis and application thereof |
CN115927420A (en) * | 2022-05-27 | 2023-04-07 | 贵州省畜牧兽医研究所 | Hemolysin recombinant expression and indirect ELISA detection method and application |
CN115925829A (en) * | 2022-07-22 | 2023-04-07 | 东北农业大学 | Application of rHtaA-c protein in preparation of vaccine for preventing Cryptobacterium pyogenes |
CN115925829B (en) * | 2022-07-22 | 2024-04-23 | 东北农业大学 | Application of rHtaA-c protein in preparation of vaccine for preventing stellera suppuration |
Also Published As
Publication number | Publication date |
---|---|
CN110967482B (en) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6637114B2 (en) | Immunological detection method and kit for Mycoplasma pneumoniae | |
CN110967482A (en) | Kit for detecting infection of cryptobacter pyogenes of goats and detection method thereof | |
CN111929433B (en) | African swine fever virus antibody ELISA detection kit and preparation method thereof | |
Fu et al. | Development of a direct competitive ELISA for the detection of Mycoplasma bovis infection based on a monoclonal antibody of P48 protein | |
CN105067812A (en) | Bovine brucella indirect ELISA antibody detection kit | |
CN113009154A (en) | One-step method novel magnetic microsphere detection kit for coronavirus neutralizing antibody and application thereof | |
WO2016121832A1 (en) | Immunological detection method and kit for mycoplasma pneumoniae | |
WO2012163263A1 (en) | Reagents and methods for prrsv detection | |
CN106771182A (en) | Brucella abortus IgM subclass antibodies indirect ELISA testing kits | |
CN106556701A (en) | Brucella melitensis indirect ELISA antibody assay kit | |
WO2023186189A2 (en) | Hybridoma cell strain secreting acta monoclonal antibody, and use thereof | |
Wang et al. | Development of an improved competitive ELISA based on a monoclonal antibody against lipopolysaccharide for the detection of bovine brucellosis | |
CN107727854A (en) | A kind of avian infectious bronchitis virus protein chip antibody assay kit and its application | |
CN110261623A (en) | A kind of detection sheep echinococcosis granulosa antibody indirect ELISA detection kit and its application | |
WO2009122714A1 (en) | Method for detection of pneumococcus | |
CN110967480A (en) | Preparation and application of pig epidemic diarrhea virus IgA antibody ELISA kit | |
CN110763843B (en) | Mycoplasma bovis double-antibody sandwich ELISA (enzyme-Linked immuno sorbent assay) detection kit and application thereof | |
JP5204036B2 (en) | Method for detecting pneumococci | |
CN1557838A (en) | SARS coronavirus nucleocapsid protein monoclonal antibody, hybridoma producing the antibody, detection reagent containing the antibody and use thereof | |
Kohler et al. | Cross-reactive urinary antigens among patients infected with Legionella pneumophila serogroups 1 and 4 and the Leiden 1 strain | |
CN114167055B (en) | Competitive enzyme-linked immunosorbent assay kit for detecting anti-African swine fever antibodies in serum | |
CN112611864B (en) | System and method for screening germ model | |
CN104678104A (en) | ELISA immunoassay kit for detecting American-type PRRS antibodies | |
CN102221619A (en) | ELISA (Enzyme-Linked Immuno Sorbent Assay) detection method and kit of cryptosporidium virus capsid protein antibody | |
Weiner et al. | Diagnosis of bovine brucellosis using traditional serological techniques and fluorescence polarisation assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |